After much speculation and anticipation, chronic care management startup Livongo officially went public on Thursday. The company closed its first day 36% above its initial pricing of $28 and is currently trading for over $41 per share on NASDAQ. The company's includes more than 12 million shares of common stock.
“It’s a signal to the market ... that [the industry] is ready for a consumer-first...
IPO fever is hitting a bit of a frenzy amidst a slew of recent listings, and with it has come a renewed focus on the exact boundaries of digital health — or, alternately, of health-tech, connected health, eHealth, or any of the other myriad monikers for the intersections of healthcare, technology and innovation.
As observers from various mainstream and niche industries have flocked to discuss ...
It's been an exceptional Thursday for Chaim Indig, CEO and cofounder of 14-year-old digital health stalwart Phreesia. Since ringing the New York Stock Exchange’s opening bell at 9:30 a.m. sharp, he’s watched his company’s shares fly back and forth in the general range of $24 to $27 per share — about 40% to 50% above the initial $18 asking price.
“All of us were up there [on stage with the bell...
Months after the first rumors began to swirl, chronic disease management startup Livongo Health has officially filed for an IPO on the Nasdaq Global Select Market.
The company has not yet determined a price range or the number of shares going on offer. Morgan Stanley & Co., Goldman Sachs & Co. and JP Morgan Securities will serve as the lead book runners.
Sources close to Livongo told...
It's been a while since the digital health space has seen an IPO. But that's about to change, according to The Wall Street Journal, which reports that chronic disease management startup Livongo Health is planning to go public this year.
According to the Journal, the company has hired Morgan Stanley, Goldman Sachs and JPMorgan Chase as underwriters, and is looking towards a valuation over $1...
Ontario-based PointClickCare, which makes a cloud-based EHR platform and other software solutions to advance senior care -- and recently launched a provider-facing app -- has raised $85 million in new funding. Dragoneer Investment Group led the round with participation from existing investor JMI Equity.
“The macro demographics of the aging population, combined with a market-wide shift in payment...
Israel-based LabStyle Innovations, maker of a smartphone-connected glucometer called Dario, has launched the device in the US, Dario secured its FDA 510(k) clearance in December.
"The US is the world's largest market for glucose monitoring and the launch of national availability represents a transformative achievement not only for Dario, but more importantly for users," LabStyle Innovations CEO...
Senseonics, a Germantown, Maryland-based company working on a longterm implantable continuous glucose monitor, has filed to go public with an IPO that, for now at least, is valued at $51.75 million.
Senseonics singular offering is a pill-sized sensor that is entirely implanted in the user’s upper arm so that it can continuously monitor their glucose levels. The device is meant to last at least...
Adherium Limited, a New Zealand company working on a smart inhaler, has raised $25.6 million ($35 million AU) in an initial public offering on the Australian Securities Exchange, including a $3 million investment from its partner pharma company AstraZeneca, which just last month announced a longterm commercialization agreement with the company.
Adherium makes a line of medical devices that...
Dallas, Texas-based video visits company Teladoc has updated its IPO filing, which now discloses that the company plans to raise $119 million in its IPO, if it is priced at the high end of its range. Teladoc will price its shares between $15 and $17. Its underwriters could raise up to an additional nearly $18 million, making for an IPO valued at as much as $136.9 million.
The company plans to ...
